Tag: Viatris
-
Viatris and Opus’ Ryzumvi Wins FDA Approval for Adult Presbyopia
Ryzumvi wins FDA approval for adult presbyopia. Explore its pupil-reducing mechanism, Phase 3 results and the commercial challenges facing Viatris and Opus Genetics.
-
Viatris to Acquire Pacira for $1.65B in Non-Opioid Pain Push
Viatris agreed to acquire Pacira BioSciences for $1.65 billion, adding Exparel, Zilretta and an established U.S. specialty platform. The deal advances Viatris’ shift toward innovative medicines but also introduces patent, generic competition and integration risks.